Globus Medical (GMED) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

14 analysts covering Globus Medical (GMED) carry an average price target of $93.43 as of November 2026, +32.5% against the $70.50 share price on November 16, 2026. The published targets run from $75.00 to $110.00, a spread of 37% of the average, so the disagreement is moderate. The rating split is 10 buy, 5 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.

GMED analyst price targets

Price
$70.50
Average target
$93.43
Median target
$95.00
Implied vs price
+32.5%
Target range
$75.00 to $110.00
Analysts covering
14
Ratings
10 buy5 hold0 sell

GMED analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 16, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.

The average target of $93.43 sits well above the $70.50 price, +32.5%. The median is $95.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

What the GMED target range actually tells you

The published targets span $75.00 to $110.00. That gap is 37% of the average target, which counts as moderate disagreement. A spread like this is fairly typical: enough agreement that the average means something, enough disagreement that it should not be treated as precise.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the GMED is it a buy page.

Recent analyst actions on GMED

FirmActionTargetPriorDate
Truist SecuritiesLowered (Buy)$90.00$100.00November 9, 2026
Canaccord GenuityLowered (Buy)$105.00$115.00November 6, 2026
Wells FargoRaised (Overweight)$100.00$99.00November 6, 2026
NeedhamLowered (Buy)$100.00$117.00November 6, 2026
BMO CapitalLowered (Market Perform)$78.00$94.00November 6, 2026
RBC CapitalLowered (Outperform)$85.00$115.00October 1, 2026
Wells FargoLowered (Overweight)$99.00$103.00August 7, 2026
UBSInitiated (Neutral)$82.00-July 28, 2026
Truist SecuritiesLowered (Buy)$100.00$115.00July 16, 2026
RBC CapitalLowered (Outperform)$115.00$120.00July 13, 2026
BMO CapitalInitiated (Outperform)$94.00-July 9, 2026
StifelLowered (Hold)$80.00$95.00July 8, 2026

The most recent published rating actions on GMED within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.

In the last six months there has been 1 raise and 9 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

How analysts rate GMED

Of the analysts with a published rating, 10 say buy, 5 say hold, and 0 say sell, so 67% carry a buy. That mix has been broadly steady over the last three months.

The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

Why a GMED price target is not a prediction

  • It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
  • The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
  • Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
  • Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

GMED earnings and revenue forecast

For the fiscal year ending Dec 2026, the 15 analysts publishing estimates on GMED expect earnings of $4.98 per share (+25% on the year before) and revenue of $3.1 billion (+5.8%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Dec 2026
next quarter to report, 14 analysts
$1.29
$1.23 to $1.32
+0.7%$783.4 million
$773.1 million to $853.9 million
-5.2%
Quarter ending Mar 2027
the quarter after, 10 analysts
$1.19
$1.09 to $1.28
+6.1%$768.5 million
$725.4 million to $795.2 million
+1.1%
Fiscal year ending Dec 2026
fiscal year next to report, 15 analysts
$4.98
$4.92 to $5.05
+25%$3.1 billion
$3.1 billion to $3.2 billion
+5.8%
Fiscal year ending Dec 2027
the fiscal year after, 15 analysts
$5.34
$5.14 to $5.52
+7.2%$3.3 billion
$3.2 billion to $3.4 billion
+5.5%

Consensus estimates for GMED published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Globus Medical next reports on November 5, 2026, which is when these figures get tested against actual results.

What Globus Medical actually reported for Q3 2026, line by line against the year before, is on the GMED earnings page.

Is there a 2030 forecast for GMED?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering GMED do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $5.34 per share, +7.2% on the fiscal year ending Dec 2026 estimate of $4.98. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, GMED trades at about 18.4 times trailing earnings and 14.0 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Globus Medical can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move GMED from here

In short: the drivers cited most often are NuVasive integration and operating leverage, Robotics as an implant channel, Competitive recruiting and international expansion. The risk cited most often against it is the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the GMED is it a buy page.

Your questions about Globus Medical

Ask Walnut's AI anything about GMED and see how it fits what you own.

FAQ

What is the price target for Globus Medical (GMED)?

+

The average analyst price target for GMED is $93.43 as of November 2026, across 14 analysts. The average is +32.5% against the $70.50 share price on November 16, 2026, so the consensus sits well above where the stock trades. The median target, which is less distorted by one extreme view, is $95.00. Targets move constantly; verify the current figure before relying on it.

How high could GMED go?

+

The highest published target is $110.00, which is +56.0% against the $70.50 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $75.00. The gap between them answers this question best: analysts who all follow Globus Medical closely disagree by 37% of the average target, so treat any single number as one scenario.

How many analysts cover GMED?

+

14 analysts publish estimates on GMED as of November 2026. Of those with a published rating, 10 say buy, 5 hold, and 0 sell, so 67% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.

Are analyst price targets for GMED accurate?

+

Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and GMED is no exception at 67% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.

Has the GMED price target been raised or cut recently?

+

In the last six months there has been 1 raise and 9 cuts among the published actions on GMED. The most recent was Truist Securities, which lowered its target to $90.00 from $100.00 on November 9, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.

What are analysts' earnings estimates for Globus Medical (GMED)?

+

For the fiscal year ending Dec 2026, the 15 analysts publishing estimates on GMED expect earnings of $4.98 per share (+25% on the year before) and revenue of $3.1 billion (+5.8%). For the fiscal year ending Dec 2027, the consensus is $5.34 per share, +7.2% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does GMED report earnings next?

+

Globus Medical's next earnings report is scheduled for November 5, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What is the GMED stock price prediction for 2030?

+

There is no published one. Analyst targets run to about twelve months and no firm covering GMED publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Globus Medical's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.

Will GMED go up in 2026?

+

Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Globus Medical: The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Walnut is not an investment adviser.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks